Aripiprazole + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Irritability Associated With Autistic Disorder
Conditions
Irritability Associated With Autistic Disorder
Trial Timeline
Mar 1, 2011 → Jun 1, 2012
NCT ID
NCT01227668About Aripiprazole + Placebo
Aripiprazole + Placebo is a approved stage product being developed by Bristol Myers Squibb for Irritability Associated With Autistic Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01227668. Target conditions include Irritability Associated With Autistic Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01227668 | Approved | Completed |
| NCT00194077 | Phase 3 | Completed |
| NCT00194012 | Phase 3 | Completed |
Competing Products
7 competing products in Irritability Associated With Autistic Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Brexpiprazole + Placebo | Lundbeck | Phase 3 | 74 |
| Brexpiprazole | Lundbeck | Phase 3 | 74 |
| JZP541 | Jazz Pharmaceuticals | Phase 2 | 49 |
| Pimavanserin | Acadia Pharmaceuticals | Phase 2/3 | 60 |
| Pimavanserin + Placebo | Acadia Pharmaceuticals | Phase 2/3 | 60 |